VO659-CT03
A Phase 2 open-label trial to investigate the long term safety of VO659 administered intrathecally in participants with Huntington’s disease and spinocerebellar ataxia type 1 and 3
Phase 2 study testing VO659 in Huntington's disease.
Not yet recruitingPhase IINot specifiedCTIS (EU)Treatment trial
Recruiting in: Denmark, France, Germany +1 more
Sponsor: Vico Therapeutics B.V.
Preparing a short plain-English summary.